15Configuring the IP Address with Wizard. 12Ĭhapter 2 Configuring the IP AddressOptions for Configuring the IP Address and Mask. 12Īccessing the Configuration from the Web Interface. 11Configure the Digi Device from the Web Interface. 11Configure the Digi Device from a Telnet Session. 11Configure the Digi Device from an Attached Terminal. 11Ĭonfigure the Digi Device with the Wizard. 10Step F: Configure Other Features as Required.
#DIGI ONE SP SOFTWARE INSTALL#
10Step C: Install and Setup Digi Port Authority-Remote. 9Online Help for the Web UI (User Interface)*. Other Documents in the Library.9Quick Start Guide. The Digi logo, Making Device Networking Easy logo, PortServer TS, Connectware, Digi One, and RealPort are trademarks or registered trademarks of Digi International, Inc.Ĭhapter 1 IntroductionAbout This Guide.9 PortServer TS 8/16 MEI, and PortServer TS 16 48V Dual Feedĭigi International Inc.
#DIGI ONE SP SOFTWARE UPDATE#
Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.Digi One & PortServer TS FamiliesDigi One SP, Digi One IA, Digi One IAP, PortServer TS MEI Family, PortServer TS W MEI Family, PortServer TS 8/16, The company assumes no duty to update the information to reflect subsequent developments. The information contained in this website was current as of the date presented. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site ( No Duty to Update The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Risks and uncertainties include but are not limited to, general industry conditions and competition general economic factors, including interest rate and currency exchange rate fluctuations the impact of the recent global outbreak of novel coronavirus disease (COVID-19) the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally global trends toward health care cost containment technological advances, new products and patents attained by competitors challenges inherent in new product development, including obtaining regulatory approval the company’s ability to accurately predict future market conditions manufacturing difficulties or delays financial instability of international economies and sovereign risk dependence on the effectiveness of the company’s patents and other protections for innovative products and the exposure to litigation, including patent litigation, and/or regulatory actions. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. Private Securities Litigation Reform Act of 1995. This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
0 kommentar(er)
